A single but durable stable disease sends the microcap's stock up 730%.
ApexOnco Front Page
Recent articles
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
First-in-human trial initiations feature Interius, Umoja and Vironexis.
Western data on EO-3021 fail to live up to the billing of a Chinese trial.
NVL-330 features among the latest crop of industry projects newly into human trials.
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.